Cell Therapeutics (UK) Ltd.

A statistically significant percentage of myelofibrosis patients treated with CTI BioPharma's pacritinib in the Phase III PERSIST-1 clinical trial had a 35% or greater reduction in spleen size versus

Privately held cancer drug developer Nordic Nanovector – a spin-out company from the same founders who built Xofigo creator Algeta – is raising NOK150m ($25m) through a private placement of shares in

NICE, the health technology appraisal institute for England and Wales, has given a final nod for both Cell Therapeutics' non-Hodgkin's lymphoma drug Pixuvri (pixantrone), and Bayer's Eylea (aflibercep

Seattle, US-based Cell Therapeutics, a biopharmaceutical company developing a portfolio of oncology products, has named Karen Ignagni to its board of directors – effective from 3 February 2014. Ms Ign